Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Profusa ( (PFSA) ) has provided an announcement.
On April 2, 2026, Profusa amended its existing securities purchase and pledge agreements, enabling the company to issue up to $12.2 million in additional senior secured convertible notes at a discount and reprioritizing repayment to favor these new instruments. As part of this financing, the company issued Ascent Partners Fund a $555,555.55 third-tranche note maturing in 2027, along with a warrant for 1,111,111 common shares at $0.50, reinforcing Profusa’s reliance on structured private capital to fund operations.
Separately, Profusa signed a non-binding letter of intent on March 31, 2026, revised April 3–4, 2026, to acquire Bio Insights’ PanOmics next-generation sequencing assets for $30 million in equity, plus a 3% revenue royalty. The proposed deal, which is subject to shareholder approval, due diligence and regulatory consents, is designed to leverage recent CMS reimbursement support for NGS oncology testing, diversify near-term revenue while LumeeOxygen completes validation, and reshape Profusa’s capital structure via substantial new share issuance and long-term lock-ups for Bio Insights and management incentives.
The transaction terms envisage issuing common and non-voting preferred stock convertible into tens of millions of shares over time, a seven-year lock-up for most of Bio Insights’ equity, and additional equity financing of $10 million to fund PanOmics validation and equipment. Governance and control features include a Bio Insights board nominee, a voting agreement in favor of Profusa board proposals, and new equity awards equal to 12% of fully diluted shares for Profusa’s CEO and CFO, aligning management retention with the success of the expanded oncology diagnostics platform.
More about Profusa
Profusa, Inc. is a Delaware-based medical technology company focused on real-time biochemical monitoring and genomic diagnostics, with an emerging strategy to build an integrated oncology platform. Its portfolio includes the LumeeOxygen monitoring technology and, through planned acquisitions, next-generation sequencing-based assays aimed at oncology and key metabolic diseases.
Average Trading Volume: 599,230
Technical Sentiment Signal: Sell
Current Market Cap: $1.03M
For an in-depth examination of PFSA stock, go to TipRanks’ Overview page.